Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

(2017) E J Cheadle et al.   LEUKEMIA

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

(2016) Laurie H Sehn et al.   LANCET ONCOLOGY

Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies

(2016) Capucine L. Grandjean et al.   Scientific Reports

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

(2015) C. L. Freeman et al.   BLOOD

Anti-CD20 Therapy Acts via Fc RIIIA to Diminish Responsiveness of Human Natural Killer Cells

(2015) C. Capuano et al.   CANCER RESEARCH

Obinutuzumab in hematologic malignancies: Lessons learned to date

(2015) Tim Illidge et al.   CANCER TREATMENT REVIEWS

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function

(2015) Heinrich Schlums et al.   IMMUNITY

Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals

(2015) Jaewon Lee et al.   IMMUNITY

Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells

(2015) Linda Quatrini et al.   Science Signaling

NK cells regulating T cell responses: mechanisms and outcome

(2015) Josh Crouse et al.   TRENDS IN IMMUNOLOGY

Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells

(2015) Linda Quatrini et al.   Science Signaling

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

(2015) M Christina Cox et al.   OncoImmunology

Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

(2014) R. P. Taylor et al.   BLOOD

Obinutuzumab

(2014) Anne-Laure Gagez et al.   CURRENT OPINION IN ONCOLOGY

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells

(2014) Rosa Molfetta et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity

(2014) G. Terszowski et al.   JOURNAL OF IMMUNOLOGY

Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

(2014) S. Herter et al.   JOURNAL OF IMMUNOLOGY

Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

(2014) C Deligne et al.   LEUKEMIA

Type I and type II Fc receptors regulate innate and adaptive immunity

(2014) Andrew Pincetic et al.   NATURE IMMUNOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

(2013) Luca Quartuccio et al.   ANNALS OF THE RHEUMATIC DISEASES

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition

(2013) Eric O. Long et al.   Annual Review of Immunology

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)

(2013) R. Romee et al.   BLOOD

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

(2013) J. Golay et al.   BLOOD

Natural cytotoxicity receptors and their ligands

(2013) Philip H Kruse et al.   IMMUNOLOGY AND CELL BIOLOGY

The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging

(2013) Fabricio Montalvao et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcR  Deficiency

(2013) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Signaling by Fyn-ADAP via the Carma1–Bcl-10–MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells

(2013) Kamalakannan Rajasekaran et al.   NATURE IMMUNOLOGY

PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway

(2012) C. Capuano et al.   BLOOD

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

(2012) D. O. Persky et al.   HAEMATOLOGICA

Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity

(2012) Jennifer T. Grier et al.   JOURNAL OF CLINICAL INVESTIGATION

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

(2011) S. Veeramani et al.   BLOOD

Differential requirements for CD45 in NK-cell function reveal distinct roles for Syk-family kinases

(2011) D. G. T. Hesslein et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site

(2011) M. G. Joyce et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

(2009) C. Fauriat et al.   BLOOD

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA